| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Zalevsky Jonathan | Chief R&D Officer | C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH, SAN FRANCISCO | Elizabeth Zhang, Attorney-in-Fact | 20 Feb 2026 | 0001789857 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NKTR | Common Stock | Sale | $13,140 | -180 | -0.84% | $73.00 | 21,174 | 18 Feb 2026 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. |
| F2 | This transaction was executed in multiple trades at prices ranging from $72.51 to $74.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. |